Legend Biotech (LEGN) Projected to Post Earnings on Wednesday

Legend Biotech (NASDAQ:LEGN) is expected to be releasing its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Legend Biotech to post earnings of ($0.08) per share and revenue of $277.9080 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 8:00 AM ET.

Legend Biotech (NASDAQ:LEGN) last announced its earnings results on Monday, August 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.12). Legend Biotech had a negative return on equity of 32.00% and a negative net margin of 40.83%.The firm had revenue of $255.06 million during the quarter, compared to the consensus estimate of $237.49 million. During the same period in the prior year, the company posted ($0.05) EPS. The firm’s revenue was up 36.8% on a year-over-year basis. On average, analysts expect Legend Biotech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Legend Biotech Stock Down 0.2%

Shares of NASDAQ:LEGN opened at $32.05 on Wednesday. Legend Biotech has a 52-week low of $27.34 and a 52-week high of $47.79. The firm has a market capitalization of $5.92 billion, a P/E ratio of -36.42 and a beta of 0.17. The stock has a 50 day moving average price of $33.19 and a 200-day moving average price of $34.47. The company has a debt-to-equity ratio of 0.30, a quick ratio of 4.57 and a current ratio of 4.71.

Analyst Ratings Changes

Several research analysts have recently issued reports on LEGN shares. Johnson Rice set a $60.00 target price on Legend Biotech in a research report on Friday, October 17th. Royal Bank Of Canada reissued an “outperform” rating and issued a $77.00 target price (up previously from $75.00) on shares of Legend Biotech in a research report on Tuesday, August 12th. JPMorgan Chase & Co. decreased their target price on Legend Biotech from $78.00 to $76.00 and set an “overweight” rating for the company in a research report on Thursday, October 9th. Morgan Stanley increased their target price on Legend Biotech from $81.00 to $83.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 12th. Finally, HC Wainwright decreased their target price on Legend Biotech from $75.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, October 17th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $66.56.

Hedge Funds Weigh In On Legend Biotech

Several institutional investors and hedge funds have recently modified their holdings of LEGN. Raymond James Financial Inc. bought a new position in shares of Legend Biotech during the second quarter valued at $78,000. First Trust Advisors LP bought a new position in shares of Legend Biotech during the second quarter valued at $411,000. Two Sigma Securities LLC bought a new position in shares of Legend Biotech during the second quarter valued at $464,000. Man Group plc bought a new position in shares of Legend Biotech during the second quarter valued at $539,000. Finally, Nomura Holdings Inc. increased its holdings in shares of Legend Biotech by 244.3% in the 2nd quarter. Nomura Holdings Inc. now owns 27,961 shares of the company’s stock worth $992,000 after purchasing an additional 19,840 shares in the last quarter. 70.89% of the stock is currently owned by institutional investors.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).